<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">39389968</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>De novo protein sequencing of antibodies for identification of neutralizing antibodies in human plasma post SARS-CoV-2 vaccination.</ArticleTitle><Pagination><StartPage>8790</StartPage><MedlinePgn>8790</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">8790</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-024-53105-8</ELocationID><Abstract><AbstractText>The antibody response to vaccination and infection is a key component of the immune response to pathogens. Sequencing of peripheral B cells may not represent the complete B cell receptor repertoire. Here we present a method for sequencing human plasma-derived polyclonal IgG using a combination of mass spectrometry and B-cell sequencing. We investigate the IgG response to the Moderna Spikevax COVID-19 vaccine. From the sequencing data of the natural polyclonal response to vaccination, we generate 12 recombinant antibodies. Six derived recombinant antibodies, including four generated with de novo protein sequencing, exhibit similar or higher binding affinities than the original natural polyclonal antibody. Neutralization tests reveal that the six antibodies possess neutralizing capabilities against the target antigen. This research provides insights into sequencing polyclonal IgG antibodies and the potential of our approach in generating recombinant antibodies with robust binding affinity and neutralization capabilities. Directly examining the circulating IgG pool is crucial due to potential misrepresentations by B-cell analysis alone.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Le Bihan</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-0498-8063</Identifier><AffiliationInfo><Affiliation>Rapid Novor, Kitchener, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nunez de Villavicencio Diaz</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-3303-8836</Identifier><AffiliationInfo><Affiliation>Rapid Novor, Kitchener, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reitzel</LastName><ForeName>Chelsea</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rapid Novor, Kitchener, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lange</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-7056-3074</Identifier><AffiliationInfo><Affiliation>Rapid Novor, Kitchener, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Minyoung</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4628-147X</Identifier><AffiliationInfo><Affiliation>Rapid Novor, Kitchener, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beadle</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Rapid Novor, Kitchener, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Lin</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-4613-4771</Identifier><AffiliationInfo><Affiliation>Rapid Novor, Kitchener, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jovic</LastName><ForeName>Marko</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0310-7730</Identifier><AffiliationInfo><Affiliation>Rapid Novor, Kitchener, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>Rosalin M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Rapid Novor, Kitchener, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couzens</LastName><ForeName>Amber L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0003-0057-6686</Identifier><AffiliationInfo><Affiliation>Rapid Novor, Kitchener, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Rapid Novor, Kitchener, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Xiaobing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Rapid Novor, Kitchener, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qixin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Rapid Novor, Kitchener, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Bin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-6254-4087</Identifier><AffiliationInfo><Affiliation>Rapid Novor, Kitchener, ON, Canada. bma@rapidnovor.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020539" MajorTopicYN="N">Sequence Analysis, Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000915" MajorTopicYN="N">Antibody Affinity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors disclose the following competing interests: B.M. and Q.L. have equity interests in Rapid Novor, a company that may potentially benefit from the research outcomes. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>0</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>23</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39389968</ArticleId><ArticleId IdType="pmc">PMC11466954</ArticleId><ArticleId IdType="doi">10.1038/s41467-024-53105-8</ArticleId><ArticleId IdType="pii">10.1038/s41467-024-53105-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lu, R. M. et al. Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci.27. 10.1186/s12929-019-0592-z (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6939334</ArticleId><ArticleId IdType="pubmed">31894001</ArticleId></ArticleIdList></Reference><Reference><Citation>Hjelm, B., Forsström, B., Löfblom, J., Rockberg, J. &amp; Uhlén, M. Parallel immunizations of rabbits using the same antigen yield antibodies with similar, but not identical, epitopes. PLoS ONE7, e45817 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3526615</ArticleId><ArticleId IdType="pubmed">23284606</ArticleId></ArticleIdList></Reference><Reference><Citation>Köhler, G. &amp; Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature256, 495–497 (1975).</Citation><ArticleIdList><ArticleId IdType="pubmed">1172191</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson, P. C. &amp; Andrews, S. F. Tools to therapeutically harness the human antibody response. Nat. Rev. Immunol. 12, 709–719 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097371</ArticleId><ArticleId IdType="pubmed">23007571</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenzel, A., Schirrmann, T. &amp; Hust, M. Phage display-derived human antibodies in clinical development and therapy. mAbs8, 1177–1194 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5058633</ArticleId><ArticleId IdType="pubmed">27416017</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedrioli, A. &amp; Oxenius, A. Single B cell technologies for monoclonal antibody discovery. Trends in Immunol.42, 1143–1158 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34743921</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung, W. C. et al. A proteomics approach for the identification and cloning of monoclonal antibodies from serum. Nat. Biotechnol.30, 447–452 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22446692</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato, S. et al. Proteomics-directed cloning of circulating antiviral human monoclonal antibodies. Nat. Biotechnol. 30 1039–1043 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23138294</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavinder, J., Wine, Y., Boutz, D., Marcotte, E. &amp; Georgiou, G. Proteomic identification of antibodies. Patent No.: US 10, 175,B2 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4033631</ArticleId><ArticleId IdType="pubmed">24684310</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgiou, G. et al. The promise and challenge of high-throughput sequencing of the antibody repertoire. Nat. Biotechnol.32 158–168 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4113560</ArticleId><ArticleId IdType="pubmed">24441474</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiller, T. et al. A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties. MAbs5, 445–470 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4169037</ArticleId><ArticleId IdType="pubmed">23571156</ArticleId></ArticleIdList></Reference><Reference><Citation>França, R. K. A. et al. Progress on phage display technology: tailoring antibodies for cancer immunotherapy. Viruses15,1903 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10536222</ArticleId><ArticleId IdType="pubmed">37766309</ArticleId></ArticleIdList></Reference><Reference><Citation>Doevendans, E. &amp; Schellekens, H. Immunogenicity of innovative and biosimilar monoclonal antibodies. Antibodies8:21 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6640699</ArticleId><ArticleId IdType="pubmed">31544827</ArticleId></ArticleIdList></Reference><Reference><Citation>Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature584, 443–449 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7584396</ArticleId><ArticleId IdType="pubmed">32668443</ArticleId></ArticleIdList></Reference><Reference><Citation>Westendorf, K. et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep.39: 110812 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9035363</ArticleId><ArticleId IdType="pubmed">35568025</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgiev, I. S. et al. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science340, 751–756 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23661761</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhary, N. &amp; Wesemann, D. R. Analyzing immunoglobulin repertoires. Front. Immunol.9. 10.3389/fimmu.2018.00462 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5861150</ArticleId><ArticleId IdType="pubmed">29593723</ArticleId></ArticleIdList></Reference><Reference><Citation>Guthals, A. et al. De novo MS/MS sequencing of native human antibodies. J. Proteome Res.16, 45–54 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5574256</ArticleId><ArticleId IdType="pubmed">27779884</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, J. et al. Proteomic analysis of pemphigus autoantibodies indicates a larger, more diverse, and more dynamic repertoire than determined by B cell genetics. Cell Rep.18, 237–247 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5221611</ArticleId><ArticleId IdType="pubmed">28052253</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank, A. &amp; Pevzner, P. PepNovo: De novo peptide sequencing via probabilistic network modeling. Anal. Chem.77, 964–973 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15858974</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma, B. et al. PEAKS: Powerful software for peptide de novo sequencing by tandem mass spectrometry. Rapid Commun. Mass Spectrom.17, 2337–2342 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14558135</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, K., Ye, Y., Li, S. &amp; Tang, H. Accurate de novo peptide sequencing using fully convolutional neural networks. Nat. Commun.14, 7974 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10693636</ArticleId><ArticleId IdType="pubmed">38042873</ArticleId></ArticleIdList></Reference><Reference><Citation>Eloff, K. et al. De novo peptide sequencing with InstaNovo: accurate, database-free peptide identification for large scale proteomics experiments. Preprint at bioRxiv10.1101/2023.08.30.555055.</Citation></Reference><Reference><Citation>Yilmaz, M., Fondrie, W. E., Bittremieux, W., Oh, S. &amp; Noble, W. S. De novo mass spectrometry peptide sequencing with a transformer model. 39th Int. Confer. Mach. Learn.162, 25514–25522 (2022).</Citation></Reference><Reference><Citation>Bandeira, N., Pham, V., Pevzner, P., Arnott, D. &amp; Lill, J. R. Automated de novo protein sequencing of monoclonal antibodies. Nat. Biotechnol.26, 1336–1338 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891972</ArticleId><ArticleId IdType="pubmed">19060866</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, X. et al. De Novo protein sequencing by combining top-down and bottom-up tandem mass spectra. J. Proteome Res. 13, 3241–3248 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24874765</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng, W., Pronker, M. F. &amp; Snijder, J. Mass spectrometry-based de novo sequencing of monoclonal antibodies using multiple proteases and a dual fragmentation scheme. J. Proteome Res.20, 3559–3566 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8256418</ArticleId><ArticleId IdType="pubmed">34121409</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondt, A. et al. Into the dark serum proteome: personalized features of IgG1 and IgA1 repertoires in severe COVID-19 patients. Mol. Cell Proteomics23. 10.1016/j.mcpro.2023.100690 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10784693</ArticleId><ArticleId IdType="pubmed">38065436</ArticleId></ArticleIdList></Reference><Reference><Citation>Thevis, M., Ogorzalek Loo, R. R. &amp; Loo, J. A. In-gel derivatization of proteins for cysteine-specific cleavages and their analysis by mass spectrometry. J. Proteome Res. 2, 163–172 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12716130</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung, W. C. et al. Evaluation of disulfide scrambling during the enzymatic digestion of bevacizumab at various pH values using mass spectrometry. Biochim Biophys. Acta Proteins Proteom.1864, 1188–1194 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27238563</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhokhov, S. S., Kovalyov, S. V., Samgina, T. Y. &amp; Lebedev, A. T. An EThcD-based method for discrimination of leucine and isoleucine residues in tryptic peptides. J. Am. Soc. Mass Spectrom.28, 1600–1611 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28447219</ArticleId></ArticleIdList></Reference><Reference><Citation>Säfsten, P., Klakamp, S. L., Drake, A. W., Karlsson, R. &amp; Myszka, D. G. Screening antibody-antigen interactions in parallel using Biacore A100. Anal. Biochem. 353, 181–190 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16510107</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray, J. B., Roughley, S. D., Matassova, N. &amp; Brough, P. A. Off-rate screening (ORS) by surface plasmon resonance. An efficient method to kinetically sample hit to lead chemical space from unpurified reaction products. J. Med. Chem.57, 2845–2850 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24520903</ArticleId></ArticleIdList></Reference><Reference><Citation>Longmire, R. L. et al. In vitro splenic igg synthesis in hodgkin’s disease. N Engl J Med. 289, 763–767 (1973).</Citation><ArticleIdList><ArticleId IdType="pubmed">4542304</ArticleId></ArticleIdList></Reference><Reference><Citation>He, B. et al. Rapid isolation and immune profiling of SARS-CoV-2 specific memory B cell in convalescent COVID-19 patients via LIBRA-seq. Signal Transduct Target Ther. 6, 195 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8127497</ArticleId><ArticleId IdType="pubmed">34001847</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouet, R. et al. Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients. Nat. Commun.14. 10.1038/s41467-023-36295-5 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9907207</ArticleId><ArticleId IdType="pubmed">36755042</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondt, A. et al. Human plasma IgG1 repertoires are simple, unique, and dynamic. Cell Syst.12, 1131–1143.e5 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691384</ArticleId><ArticleId IdType="pubmed">34613904</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, X., Han, Y., Yuen, D. &amp; Ma, B. Automated protein (re)sequencing with MS/MS and a homologous database yields almost full coverage and accuracy. Bioinformatics25, 2174–2180 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19535534</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bihan, T., Robinson, M. D., Stewart, I. I. &amp; Figeys, D. Definition and characterization of a ‘trypsinosome’ from specific peptide characteristics by Nano-HPLC-MS/MS and in silico analysis of complex protein mixtures. J. Proteome Res.3, 1138–1148 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15595722</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Y. F., Arnold, R. J., Tang, H. &amp; Radivojac, P. The importance of peptide detectability for protein identification, quantification, and experiment design in MS/MS proteomics. J. Proteome Res. 9, 6288–6297 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3006185</ArticleId><ArticleId IdType="pubmed">21067214</ArticleId></ArticleIdList></Reference><Reference><Citation>Bache, N. et al. A novel LC system embeds analytes in pre-formed gradients for rapid, ultra-robust proteomics. Mol Cell Proteomics. 17, 2284–2296 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6210218</ArticleId><ArticleId IdType="pubmed">30104208</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann, M., Hendrickson, R. C. &amp; Pandey, A. Analysis of proteins and proteomes by mass spectrometry. Annu. Rev. Biochem. 70, 10.1146/annurev.biochem.70.1.437 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11395414</ArticleId></ArticleIdList></Reference><Reference><Citation>Krusemark, C. J., Frey, B. L., Smith, L. M. &amp; Belshaw, P. J. Complete chemical modification of amine and acid functional groups of peptides and small proteins. Methods Mol. Biol.753, 77–91 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3859371</ArticleId><ArticleId IdType="pubmed">21604117</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma, B. Novor: real-time peptide de novo sequencing software. J. Am. Soc. Mass Spectrom.26, 1885–1894 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4604512</ArticleId><ArticleId IdType="pubmed">26122521</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu, S. et al. Mapping native disulfide bonds at a proteome scale. Nat. Methods12, 329–331 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25664544</ArticleId></ArticleIdList></Reference><Reference><Citation>Raybould, M. I. J., Kovaltsuk, A., Marks, C. &amp; Deane, C. M. CoV-AbDab: the coronavirus antibody database. Bioinformatics37, 734–735 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7558925</ArticleId><ArticleId IdType="pubmed">32805021</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>